Literature DB >> 10072423

A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease.

N Abbas1, C B Lücking, S Ricard, A Dürr, V Bonifati, G De Michele, S Bouley, J R Vaughan, T Gasser, R Marconi, E Broussolle, C Brefel-Courbon, B S Harhangi, B A Oostra, E Fabrizio, G A Böhme, L Pradier, N W Wood, A Filla, G Meco, P Denefle, Y Agid, A Brice.   

Abstract

Autosomal recessive juvenile parkinsonism (AR-JP, PARK2; OMIM 602544), one of the monogenic forms of Parkinson's disease (PD), was initially described in Japan. It is characterized by early onset (before age 40), marked response to levodopa treatment and levodopa-induced dyskinesias. The gene responsible for AR-JP was recently identified and designated parkin. We have analysed the 12 coding exons of the parkin gene in 35 mostly European families with early onset autosomal recessive parkinsonism. In one family, a homozygous deletion of exon 4 could be demonstrated. By direct sequencing of the exons in the index patients of the remaining 34 families, eight previously undescribed point mutations (homozygous or heterozygous) were detected in eight families that included 20 patients. The mutations segregated with the disease in the families and were not detected on 110-166 control chromosomes. Four mutations caused truncation of the parkin protein. Three were frameshifts (202-203delAG, 255delA and 321-322insGT) and one a nonsense mutation (Trp453Stop). The other four were missense mutations (Lys161Asn, Arg256Cys, Arg275Trp and Thr415Asn) that probably affect amino acids that are important for the function of the parkin protein, since they result in the same phenotype as truncating mutations or homozygous exon deletions. Mean age at onset was 38 +/- 12 years, but onset up to age 58 was observed. Mutations in the parkin gene are therefore not invariably associated with early onset parkinsonism. In many patients, the phenotype is indistinguishable from that of idiopathic PD. This study has shown that a wide variety of different mutations in the parkin gene are a common cause of autosomal recessive parkinsonism in Europe and that different types of point mutations seem to be more frequently responsible for the disease phenotype than are deletions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072423     DOI: 10.1093/hmg/8.4.567

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  121 in total

1.  Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects.

Authors:  M Periquet; C Lücking; J Vaughan; V Bonifati; A Dürr; G De Michele; M Horstink; M Farrer; S N Illarioshkin; P Pollak; M Borg; C Brefel-Courbon; P Denefle; G Meco; T Gasser; M M Breteler; N Wood; Y Agid; A Brice
Journal:  Am J Hum Genet       Date:  2001-02-14       Impact factor: 11.025

2.  Exclusion of the Nurr1 gene in autosomal recessive Parkinson's disease.

Authors:  Nina Rawal; Magali Periquet; Alexandra Dürr; Giuseppe de Michele; Vincenzo Bonifati; Helio A Teive; Salmo Raskin; Joao Guimaraes; Yves Agid; Alexis Brice
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

3.  Parkin transcript variants in rat and human brain.

Authors:  Velia Dagata; Sebastiano Cavallaro
Journal:  Neurochem Res       Date:  2004-09       Impact factor: 3.996

4.  Parkin mono-ubiquitinates Bcl-2 and regulates autophagy.

Authors:  Dong Chen; Feng Gao; Bin Li; Hongfeng Wang; Yuxia Xu; Cuiqing Zhu; Guanghui Wang
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

Review 5.  Parkin plays a role in sporadic Parkinson's disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

6.  Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease.

Authors:  M Martinez; A Brice; J R Vaughan; A Zimprich; M M B Breteler; G Meco; A Filla; M J Farrer; C Bétard; J Hardy; G De Michele; V Bonifati; B Oostra; T Gasser; N W Wood; A Dürr
Journal:  J Med Genet       Date:  2004-12       Impact factor: 6.318

7.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

8.  Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson's disease.

Authors:  José A G Agúndez; Antonio Luengo; Oscar Herráez; Carmen Martínez; Hortensia Alonso-Navarro; Félix Javier Jiménez-Jiménez; Elena García-Martín
Journal:  Neuromolecular Med       Date:  2007-11-06       Impact factor: 3.843

9.  Somatic mutation of PARK2 tumor suppressor gene is not common in common solid cancers.

Authors:  Eun Mi Je; Nam Jin Yoo; Sug Hyung Lee
Journal:  Pathol Oncol Res       Date:  2012-12-08       Impact factor: 3.201

10.  Editor's Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice.

Authors:  Eileen M Martinez; Alison L Young; Yash R Patankar; Brent L Berwin; Li Wang; Katharine M von Herrmann; Jaclyn M Weier; Matthew C Havrda
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.